tbuckley/cabot-search huggingface dataset:
Cat-Scratch Disease in Children—Texas, September 2000–August 2001
Journal: JAMA (2002)

Cat-scratch disease (CSD), a bacterial infection caused by Bartonella henselae, has emerged as a relatively common and occasionally serious zoonotic disease among children and adults. To illustrate the spectrum of clinical manifestations of CSD observed during a 1-year period, Texas Children's Hospital (TCH) in Houston reviewed the medical records of 32 children evaluated at TCH during September 2000-August 2001 whose antibody titers indicated recent Bartonella infection. This report summarizes the evaluations of these cases and highlights four manifestations of infection with this pathogen in children. The findings emphasize that although CSD is generally a mild, self-limited illness, the differential diagnosis often includes more serious conditions (e.g., lymphoma, carcinoma, mycobacterial or fungal infection, or neuroblastoma) that might result in protracted hospital stays and lengthy treatments before diagnosis. Timely assessment of CSD is important, particularly when invasive diagnostic measures are being considered.
Serum Cholesterol as a Prognostic Factor after Myocardial Infarction
Authors: Mark R. Goldstein
Journal: Annals of Internal Medicine (1992)

Letters1 March 1992Serum Cholesterol as a Prognostic Factor after Myocardial InfarctionMark R. Goldstein, MDMark R. Goldstein, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-5-425 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: In men with baseline cardiovascular disease, there appears to be a direct relation between increasing cholesterol levels and subsequently increasing cardiovascular and all-cause mortality (1). In contrast, according to the Framingham data presented by Wong and colleagues (2), the relative risk for both coronary death and all-cause death in women who recovered from myocardial infarction was lower in those with cholesterol levels between 5.17 and 7.11 mmol/L (200 and 274 mg/dL) than in those with levels of less than 5.17 mmol/L (200 mg/dL) (P > 0.05).In a large population study conducted in Scotland (3), which did...References1. Pekkanen J. Relation of cholesterol level to cardiovascular mortality among men with and without preexisting cardiovascular disease. N Engl J Med. 1991;324:61. MedlineGoogle Scholar2. WongWilsonKannel NPW. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 1991;115:687-93. LinkGoogle Scholar3. IslesHoleGillisHawthorneLever CDCVA. Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. BMJ. 1989;298:920-4. CrossrefMedlineGoogle Scholar4. ForetteTortratWolmark BDY. Cholesterol as a risk factor for mortality in elderly women. Lancet. 1989;1:868-70. CrossrefMedlineGoogle Scholar5. Goldstein M. Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil. JAMA. 1990;264:2991. CrossrefMedlineGoogle Scholar1. WongWilsonKannel NPW. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 1991;115:687-93. LinkGoogle Scholar2. KaneMalloyPortsPhillipsDiehlHavel JMTNJR. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-12. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Crozer-Chester Medical Center Upland, PA 19013 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1992Volume 116, Issue 5Page: 425-426KeywordsCardiovascular disease riskCardiovascular diseasesCholesterolMortalityMyocardial infarctionRelative risk Issue Published: 1 March 1992 PDF DownloadLoading ...
Members of the House of Delegates
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights of This Issue
Journal: Clinical Cancer Research (2016)

Preclinical evaluation of targeted therapies does not follow simple criteria and often heavily relies on the use of patient-derived xenograft (PDX), which present major disadvantages: potential failure of tumor transplantation, long waiting-time to response evaluation, and extensive laboratory cost.Alternative clinical decision-making tools, therefore, are needed.This study compares PDX-based treatment response of targeted therapies in lung cancer patients with the result of a specific in silico response prediction (ISRP) tool and provides evidence for a substantial agreement between an ISPR and PDX response prediction.The ISPR allows fast and cheap individual-targeted response prediction in parallel for several substances. Heterogeneity of PD-L1
Letter: Familial neuroblastoma and ganglioneuroma
Authors: J. V. Bond
Journal: JAMA (1976)

<h3>To the Editor.—</h3> In their report of a case of neuroblastoma in father and son, Arenson et al (235:727, 1976) suggest that the incidence of familial neuroblastoma may be greater than that observed to date, one reason being that the tumor may regress spontaneously or mature to a more benign lesion, particularly in infants. It is only relatively recently that the significance of familial cases of the embryonal tumors has begun to be appreciated. Many of these cases may well have gone unreported in the past. In a recent retrospective survey of children seen at this hospital with neuroblastoma,<sup>1</sup>a further case was found involving mother and son. <h3>Report of a Case.—</h3> A 3-year-old boy had an abdominal mass that was found during a routine examination. An intravenous pyelogram demonstrated a calcified mass displacing the right kidney downwards. The vanillylmandelic acid level was 31.5 mg/24 hours. There was roentgenographic evidence
Highlights of This Issue
Journal: Clinical Cancer Research (2012)

The taxanes paclitaxel and docetaxel are widely used for the treatment of solid tumors. Recently, it was shown that cigarette smoking can influence the metabolism and toxicity profile of some important anticancer drugs. de Graan and colleagues designed a study to assess the influence of smoking on the metabolism and toxicities of taxane therapy. The pharmacokinetics of paclitaxel and docetaxel were not altered by smoking, but interestingly, smokers were found to have less hematologic toxicity during anticancer treatment.Approximately 5% to 10% of gastrointestinal stromal tumors (GIST) have pathogenetic activating mutations of the platelet-derived growth factor receptor (PDGFRA) tyrosine kinase. The most common variant, PDGFRA D842V, is resistant to currently approved tyrosine kinase inhibitors (TKI). Treatment of PDGFRA D842V–mutant GIST with conventional TKIs results in markedly inferior clinical outcomes compared with treatment of KIT-mutant GIST. Heinrich and colleagues identified crenolanib as a potent inhibitor of PDGFRA D842V with an IC50 of approximately 10 nmol/L (making it 100–150 times more potent than imatinib). Based on these results, a phase II study of crenolanib for advanced PDGFRA D842V–mutant GIST has been initiated (NCT01243346).Giant-cell tumor of bone (GCTB) is an aggressive osteolytic tumor characterized by osteoclast-like giant cells and their precursors that express RANK and mononuclear stromal cells that express the ligand RANKL, a key mediator of osteoclast activation. Denosumab binds to RANKL, eliminating giant cells, inhibiting bone destruction, and shifting the bone turnover balance in favor of bone formation. Branstetter and colleagues report that histologic evidence confirms these effects and shows that denosumab-induced interruption of the dysregulated overexpression of RANKL reduces tumor growth and promotes differentiation to normal tissue. This unique biologic mechanism is clinically relevant for GCTB treatment and for future cancer research.Docetaxel is extensively metabolized in the liver, but mechanisms by which the drug is taken up into hepatocytes remain unclear. de Graan and colleagues designed a translational study to investigate the influence of the OATP1B uptake transporters on docetaxel metabolism in transfected cell models, transporter knockout mice, and patients with inherited, reduced-function variants in the genes encoding these transporters. These findings shed new light on factors affecting the elimination of this widely used drug and provide a framework for future investigations aimed at tailoring drug dosage in cancer patients.
What Does Authorship Mean in a Peer-Reviewed Medical Journal?
Authors: George D. Lundberg
Journal: JAMA (1996)

Authorship should convey appropriate credit and establish appropriate responsibility for work done and published.<sup>1</sup>For many years,<i>JAMA</i>has asked all authors to sign an authorship responsibility statement certifying that they have met the following criteria: I have participated sufficiently in the conception and design of this work and the analysis of the data (when applicable) as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere, except as described in an attachment. If requested, I shall produce the data upon which the manuscript is based for examination by the editors or their assignees. We also have signature forms for financial disclosure, copyright
Adult Blood Lead Epidemiology and Surveillance—United States, 1992-1994
Journal: JAMA (1994)

Lead exposure can result in acute or chronic adverse effects in multiple organ systems, ranging from subclinical changes in function to symptomatic, life-threatening toxicity. Despite improvements in public health policies and substantial reductions in blood lead levels (BLLs) in adults, lead exposure remains an important health problem worldwide. Approximately 95% of all elevated BLLs reported among adults in the United States are work-related, and recent research has raised concerns regarding the toxicity of BLLs as low as 5 μg/dL. CDC's state-based Adult Blood Lead Epidemiology and Surveillance (ABLES) program tracks laboratory-reported elevated BLLs. To update rate trends and identify industry subsectors and nonoccupational activities with high lead exposures, CDC collected and analyzed 2008--2009 data from 40 state ABLES programs. The results of that analysis indicated that a decline in the prevalence of elevated BLLs (≥25 μg/dL) was extended, from 14.0 per 100,000 employed adults in 1994 to 6.3 in 2009. Industry subsectors with the highest numbers of lead-exposed workers were battery manufacturing, secondary smelting and refining of nonferrous metals, and painting and paper hanging. The most common nonoccupational exposures to lead were shooting firearms; remodeling, renovating, or painting; retained bullets (gunshot wounds); and lead casting. The findings underscore the need for government agencies, employers, public health professionals, health-care providers, and worker-affiliated organizations to increase interventions to prevent workplace lead exposure, and the importance of conducting lead exposure surveillance to assess the effectiveness of these interventions.
Doctors Across the Sea
Authors: Ralph Crawshaw
Journal: JAMA (1984)

BY SHARING our clinical experience on a direct one— to-one basis, practicing physicians in the United States can make a substantial difference in medical care throughout the world. The concerned physician can make a unique contribution through the proposed Doctor-to-Doctor International Medical Education Exchange mobilizing two-way medical communication between physicians in developing countries and the United States. Although appreciated by few, our country's diminished support of international medical education presents a problem to world health. Threatened by an overabundance of physicians in the United States, our federal policymakers have raised stringent immigration barriers against aspiring physicians from foreign lands who wish to study in the United States, largely for fear they will not return home but remain to practice medicine in the United States. No longer is there an abundance of training slots or even good will for foreign students of medicine. In fact, the plight of foreign physicians is
Core Curriculum in Allied Health Education
Authors: Joseph Hamburg
Journal: JAMA (1969)

In recent months the allied health professions have been enjoying a great deal of attention from educators interested in the development of a core curriculum. Although at one time or another almost every academic area has been a focus for similar interest, none can claim to be a more likely or persistent cynosure. What is there about these health related specialties which have made them so attractive a target for this activity? First, the very name allied health professions suggests that there exists among this diverse group a commonality of objectives as well as a sense of teamwork, and implicit in this is the likelihood that there is or should be a sharing of learning experiences. More important, however, is their sheer weight of numbers. No other group of health professionals augurs to grow as rapidly as this burgeoning collection of disciplines. Many of us concerned with the delivery of
Coronary Angioplasty Volume-Outcome Relationships for Hospitals and Cardiologists
Authors: Edward L. Hannan
Journal: JAMA (1997)

<h3>Objective.</h3> —To assess the relationship between each of 2 provider volume measures (annual hospital volume and annual cardiologist volume) for percutaneous transluminal coronary angioplasty (PTCA) and 2 outcomes of PTCA (in-hospital mortality and same-stay coronary artery bypass graft [CABG] surgery). <h3>Design.</h3> —Cohort study, using data from January 1,1991, through December 31, 1994, from the Coronary Angioplasty Reporting System of the New York State Department of Health. <h3>Setting.</h3> —Thirty-one hospitals in New York State in which PTCA was performed during 1991-1994. <h3>Patients.</h3> —All 62 670 patients discharged after undergoing PTCA in these hospitals during 1991-1994. <h3>Main Outcome Measures.</h3> —Rates of in-hospital mortality and CABG surgery during the same stay as the PTCA. <h3>Results.</h3> —The overall in-hospital mortality rate for patients undergoing PTCA in New York during 1991-1994 was 0.90%, and the same-stay CABG surgery rate was 3.43%. Patients undergoing PTCA in hospitals with annual PTCA volumes less than 600 experienced a significantly higher risk-adjusted in-hospital mortality rate of 0.96% (95% confidence interval [CI], 0.91%-1.01%) and risk-adjusted same-stay CABG surgery rate of 3.92% (95% CI, 3.76%-4.08%). Patients undergoing PTCA by cardiologists with annual PTCA volumes less than 75 had mortality rates of 1.03% (95% CI, 0.91%-1.17%) and same-stay CABG surgery rates of 3.93% (95% CI, 3.65%-4.24%); both of these rates were also significantly higher than the rates for all patients. Also, same-stay CABG surgery rates for patients undergoing PTCA in hospitals with annual volumes of 600 to 999 performed by cardiologists with annual volumes of 75 to 174 (2.99%; 95% CI, 2.69%-3.31%) and 175 or more (2.84%; 95% CI, 2.57%-3.14%) were significantly lower than the overall statewide rate (3.43%). <h3>Conclusions.</h3> —In New York State, both hospital PTCA volume and cardiologist PTCA volume are significantly inversely related to in-hospital mortality rate and same-stay CABG surgery rate for patients undergoing PTCA.
WHO Wants Rapid Response to Emerging Threats
Authors: Phil Gunby
Journal: JAMA (1996)

AMONG EFFORTS to cope with new and reemerging microbial threats is that of the World Health Organization (WHO), an autonomous unit within the United Nations system with headquarters in Geneva, Switzerland. Last fall, the WHO established a Division of Emerging, Viral, and Bacterial Diseases Surveillance and Control. This division, the WHO claims, "can mobilize rapid response teams of WHO staff and other international experts in response to epidemic threats and place them on the site of the outbreak within 24 hours." Through the WHO's regional offices, the division is trying to strengthen the epidemiologic surveillance and public health laboratories of as many of its 190 member nations as possible. In effect, it is seeking greater international participation in the WHO's network for monitoring antimicrobial resistance, tracking frequent communicable diseases like influenza, and watching for new or reemerging public health threats. <h3>Typical Reemerging Diseases</h3> In addition to dramatic outbreaks such as
Accuracy of Physicians' Office Laboratory Results
Authors: J. Eugene Huffstutter
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Production of Hepatomas in Suckling Mice After Single Application of β-Propiolactone&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1970)

β-Propiolactone (0.1 mg/g body weight), when injected intraperitoneally into (C57BL/6 × A)F1 mice on the 8th–10th day after birth, produced an average of 2 hepatomas per animal in 65% of the males 16 months after treatment. In adult mice and controls, the incidence was 9 and 4–6.7%, respectively. A dose of 0.6 mg/g body weight applied once to the skin of suckling mice yielded hepatomas in 19.4% of the animals. Treated females developed few hepatomas, though 16–20% bore malignant lymphomas (5.5% in controls). Microscopically the hepatomas were trabecular or solid, with hematopoietic embryonal cells and tumor cell embolism in veins, but without metastases at sites other than the liver.
Activity of Lymphoid Cells Separated From Mammary Tumors in Blastogenesis and Winn Assays&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: Beverly A. Blazar, Calbert A. Laing, Fred R. Miller, Gloria H. Heppner
 7
Journal: JNCI Journal of the National Cancer Institute (1980)

Lymphoid cells isolated from mouse mammary tumors by isokinetic gradients were not stimulated in vitro by either phytohemagglutinin or a soluble, tumor-associated antigen extract even though splenocytes from the tumor-bearing mice were responsive to both. In in vivo Winn assays, lymphoid cells isolated from tumors markedly stimulated tumor growth rate. The effect on growth rate was abrogated by exposure of the isolated lymphoid cells to antilymphocyte serum and complement.
Nonindustrial Chemicals as Possible Factors in the Etiology of Bladder Cancer
Authors: James M. Price
Journal: JNCI Journal of the National Cancer Institute (1969)

Journal Article Nonindustrial Chemicals as Possible Factors in the Etiology of Bladder Cancer Get access James M. Price James M. Price Division of Experimental Therapy, Abbott Laboratories, North Chicago, Illinois 60064 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 43, Issue 1, July 1969, Pages 293–294, https://doi.org/10.1093/jnci/43.1.293 Published: 01 July 1969
Psychotic Symptoms With Griseofulvin
Authors: George Lastnick
Journal: JAMA (1974)

<h3>To the Editor.—</h3> Presented here is a report of a patient with severe psychosis, headache, and microvesicular eruption after treatment with griseofulvin. We believe that this is the first reported instance of these simultaneous findings. <h3>Report of a Case.—</h3> A 61-year-old woman was hospitalized because of severe headache, depression, impaired memory, confusion, and auditory hallucinations. These symptoms had begun four days earlier, after a month of continuous therapy with griseofulvin for a fungus infection of her feet. We found a microvesicular eruption over the occipital area. Otherwise, all was within normal limits. Griseofulvin therapy was discontinued and her symptoms subsided after one week. <h3>Comment.—</h3> Griseofulvin is an effective and remarkably safe drug for systemic treatment of some fungus infections. The side effects, usually mild and temporary, include blurring of vision, skin irritations, vertigo, headache, dryness of the mouth, nausea, diarrhea, abdominal cramping, urinary frequency, and arthralgia.<sup>1</sup>Other reversible side
Awards, Appointments, Announcements
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Awards, Appointments, Announcements Get access JNCI: Journal of the National Cancer Institute, Volume 81, Issue 9, 3 May 1989, Pages 662–663, https://doi.org/10.1093/jnci/81.9.662 Published: 03 May 1989
Change in Growth and Morphology of Fibroblasts by Prostaglandins
Authors: George S. Johnson, Ira Pastan
Journal: JNCI Journal of the National Cancer Institute (1971)

Prostaglandins E1, B1, and F2α caused morphologic changes in L-929 cells and mouse embryo fibroblasts growing at low cell density similar to those produced by N6,O2'-dibutyryl cyclic adenosine monophosphate. The cell bodies elongated and the cellular processes were greatly extended. The prostaglandins also slowed cell growth and increased adhesion to the substratum. Since prostaglandins activate adenyl cyclase and raise intracellular levels of cyclic AMP, these effects were probably mediated through cyclic AMP. When confluent, the prostaglandin-treated L-929 cells resembled morphologically cells maintained in serumfree media. They lost their elongated cellular processes and became more round and flat.